Effects of various selective estrogen receptor modulators with or Without conjugated estrogens on mouse mammary gland

Endocrinology

Volumn 150, Issue 4, 2009, Pages 1897-1903

  Peano, Bryan J ^a   Crabtree, Judy S ^a   Komm, Barry S ^a   Winneker, Richard C ^a   Harris, Heather A ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; BAZEDOXIFENE; CONJUGATED ESTROGEN; LASOFOXIFENE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; FEMALE; MAMMARY GLAND; MARKER GENE; MOUSE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; WEIGHT GAIN;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGENS, CONJUGATED (USP); FEMALE; GLYCOPROTEINS; INDOLES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MAMMARY GLANDS, ANIMAL; MICE; MICE, INBRED C57BL; ORGAN SIZE; POLYMERASE CHAIN REACTION; PYRROLIDINES; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TETRAHYDRONAPHTHALENES; UTERUS;

EID: 63849224133     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2008-1210     Document Type: Article

References (29)

1. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, Strom A, Treuter E, Warner M, Gustafsson JA 2007 Estrogen receptors: how do they signal and what are their targets. Physiol Rev 87:905-931
2. Chambliss KL, Shaul PW 2002 Estrogen modulation of endothelial nitric oxide synthase. Endocr Rev 23:665-686
3. Kelly MJ, Ronnekleiv OK 2008 Membrane-initiated estrogen signaling in hypothalamic neurons. Mol Cell Endocrinol 290:14-23
4. Simpkins JW, Yang S, Sarkar SN, Pearce V 2008 Estrogen actions on mitochondria-physiological and pathological implications. Mol Cell Endocrinol 290:51-59
5. Levin ER, Pietras RJ 2008 Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Res Treat 108:351-361
6. Prossnitz ER, Arterburn JB, Smith HO, Oprea TI, Sklar LA, Hathaway HJ 2008 Estrogen signaling through the transmembrane G protein-coupled receptor GrPR30. Annu Rev Physiol 70:165-190
7. Anstead GM, Carlson KE, Katzenellenbogen JA 1997 The estradiol pharmacophore-ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids 62:268-303
8. Gao H, Katzenellenbogen JA, Garg R, Hansch C 1999 Comparative QSAR analysis of estrogen receptor ligands. Chem Rev 99:723-744
9. Miller CP 2002 SERMs: evolutionary chemistry, revolutionary biology. Curr Pharmaceut Design 8:2089-2111
10. McDonnell DP, Chang CY, Norris JD 2001 Capitalizing on the complexities of estrogen receptor pharmacology in the quest for the perfect SERM. Ann NY Acad Sci 949:16 -35
11. Katzenellenbogen JA, O'Malley BW, Katzenellenbogen BS 1996 Tripartite steroid hormone receptor pharmacology-interaction with multiple effector sites as a basis for the cell- and promoter-specific action ofthese hormones. Mol Endocrinology 10:119 -131
12. McDonnell DP 2004 The molecular determinants of estrogen receptor pharmacology. Maturitas 48(Suppl 1):S7-S12
13. Buelke-Sam J, Bryant HU, Francis PC 1998 The selective estrogen receptor modulator, raloxifene: an overview of nonclinical pharmacology and reproductive and developmental testing. Reprod Toxicol 12:212-221
14. Inal MM, Incebiyik A, Sanci M, Yildirim Y, Polat M, Pilanci B, Nayki C, Camuzcuoglu H 2005 Ovarian cysts in tamoxifen-treated women with breast cancer. Eur J Obstet Gynecol Reprod Biol 120:104-106
15. Premkumar A, Venzon DJ, Avila N, Johnson DV, Remaley AT, Forman MR, Eng-Wong J, Zujewski J, Stratton P 2007 Gynecologic and hormonal effects of raloxifene in premenopausal women. Fertil Steril 88:1637-1644
16. Fendrick JL, Raafat AM, Haslam SZ 1998 Mammary gland growth and development from the postnatal period to postmenopause: ovarian steroid receptor ontogeny and regulation in the mouse. J Mamm Gland Biol Neoplasia 3:7-22
17. Komm BS, Kharode YP, Bodine PVN, Harris HA, Miller CP, Lyttle CR 2005 Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 146:3999-4008
18. Lewiecki EM 2007 Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis. Expert Opin Investig Drugs 16:1663-1672
19. Kharode YP, Bodine PVN, Miller CP, Lyttle CR, Komm BS 2008 Thepairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology 149:6084-6091
20. Crabtree JS, Zhang X, Peano BJ, Zhang Z, Winneker RC, Harris HA 2006 Development of a mouse model of mammary gland versus uterus tissue selectivity using estrogen- and progesterone-regulated gene markers. J Steroid Biochem Mol Biol 101:11-21
21. Anonymous 2006 National Institute of Standards and Technology/Semiconductor Manufacturing Technology e-handbook of statistical methods. http://www.itl.nist.gov/div898/handbook/
22. Ciarloni L, Mallepell S, Brisken C 2007 Amphiregulin is an essential mediator of estrogen receptor alpha function in mammary gland development. Proc Natl Acad Sci USA 104:5455-5460
23. Shelly W, Draper MW, Krishnan V, Wong M, Jaffe RB 2008 Selective estrogen receptor modulators: an update on recent clinical findings. Obstet Gynecol Surv 63:163-181
24. Hattersley G, Paquin DG, HoS, MerchenthalerI, OgasawaraA, Nakagawa M, Ogura H, Lyttle CR, RAD-1901, a novel SERM, has efficacy in an animal model of vasomotor symptoms. Program of the 89th Annual Meeting of The Endocrine Society, Toronto, Canada, June 2-5, 2007, (Abstract P1-415)
25. Jain N, Kanojia RM, Xu J, Jian-Zhong G, Pacia E, Lai M-T, Du F, Musto A, Allan G, Hahn D, Lundeen S, Sui Z 2006 Novel chromene-derived selective estrogen receptor modulators useful for alleviating hot flushes and vaginal dryness. J Med Chem 40:3056-3059
26. Wallace OB, Lauwers KS, Dodge JA, May SA, Calvin JR, Hinklin R, Bryant HU, Shetler PK, Adrian MD,Geiser AG, Sato M, Burris TP 2006 Aselective estrogen receptor modulator for the treatment of hot flushes. J Med Chem 49:843-846
27. Stovall DW, Utian WH, Gass MLS, Qu YM, Muram D, Wong M, Plouffe L 2007 The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. Menopause 14:510-517
28. Miller PD, Chines AA, Christiansen C, HoeckHC, Kendler DL, Lewiecki EM, Woodson G, Levine AB, Constantine G, Delmas PD 2008 Effects ofbazedox- ifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 23:525-535
29. Crabtree JS, Peano BJ, Zhang X, Komm BS, Winneker RC, Harris HA 2008 Activity of three selective estrogen receptor modulators on hormone-dependent responses in the mouse uterus and mammary gland. Mol Cell Endocrinol 287: 40-46